Disregard Everything I Say: Archive

3-MeO-PCMo, broken down and described

Dosage (oral)
Threshold: 100mg
Light: 100 - 300mg
Common: 300 - 600mg
Strong: 600 - 900mg
Heavy: 900mg +

Duration (oral)
Total duration: 5 - 6 hours
Onset: 1 - 2 hours
Peak: 2 - 3 hours
Come down: 1 - 2 hours
After effects: 2 - 3 hours

3-MeO-PCMo (4-[1-(3-methoxyphenyl)cyclohexyl]morpholine) is a new morpholine analogue of 3-MeO-PCP. It is a dissociative NMDA receptor antagonist and anesthetic drug of the arylcyclohexylamine chemical class with a potency of less than 1/10th of that of 3-MeO-PCP.

This compound induces a state referred to as “dissociative anesthesia” when ingested and is therefore used as a recreational drug. 3-MeO-PCMo has recently become freely available through online research chemical vendors^[1] where it is being sold as a designer drug.

Although very little is known about this compound, similar morpholine analogues of phencyclidine have been researched before.^[2]^[3]

In terms of its chemistry, 3-MeO-PCMo, or 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine, is classified as an arylcyclohexylamine drug. Ayrlcyclohexylamine drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group at the same location. The aryl substituent of 3-MeO-PCMo is a phenyl ring with a methoxy (CH₃-O-) substituent at R₃, which is bound to a six-membered cyclohexyl ring. Bound at the same location on the cyclohexyl ring R₁ is an amine group which is incorporated into a morpholine ring as R₄. Morpholine is a six-membered heterocyclic ring with an oxygen subsitutent at R₁. 3-MeO-PCMo is a morpholine analogue to 3-MeO-PCP, which lacks an oxygen moiety in its six-membered amine ring (a piperidine ring instead of a morpholine ring).

In terms of its pharmacology, due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other arylcyclohexylamine dissociatives such as 3-MeO-PCP, PCP and MXE. With this in mind, 3-Meo-PCMo is thought to act as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. NMDA receptor antagonists close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually the famous “hole.”

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects:

The subjective physical effects of 3-MeO-PCMo can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:

Spontaneous tactile sensations - The 3-MeO-PCMo body high is a soft, warm, motionless and pleasurable tingling sensation which is all-encompassing across the body and not location specific to any area.
Decreased bodily weight - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
Nausea - It’s worth noting that high dose 3-MeO-PCMo trips can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
Motor control loss - A loss of gross and fine motor control alongside of balance and coordination is prevalent within 3-MeO-PCMo and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in case of falling over and injuring oneself.
Physical euphoria
Tactile disconnection
Tactile suppression
Physical autonomy

Cognitive effects:

The general head space of 3-MeO-PCMo is often described as simplistic and shallow in comparison to that of MXE and ketamine. The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:

Visual effects:

Suppressions:

This substance does not enhance visual stimuli; instead, it tends to degrade and decrease visual aptitude in a variety of ways which generally include:

Visual disconnection - This eventually results in the 3-MeO-PCMo equivalent of the famous “k-hole” or, more specifically, holes, spaces and voids alongside of structures.
Double vision - This component is prevalent at moderate to heavy doses and makes reading impossible unless one closes an eye.
Pattern recognition suppression - This effect generally occurs at higher doses and makes one unable to recognize and interpret perceivable visual data.
Visual acuity suppression

Distortions:

Perspective distortions

Geometry:

The visual geometry found within 3-MeO-PCMo can be described as very dark and bland when compared to that of ketamine or DXM. It often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 geometry and can be comprehensively described through its variations as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.

Auditory effects:

Physical health effects, potential addiction and tolerance:

The toxicity and long-term health effects of recreational 3-MeO-PCMo use have not been studied in any scientific context and the exact toxic dose is unknown. This is because 3-MeO-PCMo is a research chemical with very little history of human usage. Anecdotal evidence from people who have tried 3-MeO-PCMo within the psychonaut community suggests that there are no negative health effects attributed to simply trying this drug at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed).

There is a tolerance build up with 3-MeO-PCMo which results in the need to consume increasingly large doses in order to achieve the same level of effects. This should reset to baseline after 1 - 2 weeks. There may be some addictive potential, but this is still unknown.

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 3-MeO-PCMo seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, MXE and other arylcyclohexylamines, but to an even more extreme extent. This is because 3-MeO-PCMo is 50% less potent than that of ketamine which means significantly more of the drug must be consumed in order to achieve the same effects. Symptoms of 3-MeO-PCMo-induced cystitis can become extremely serious and can be described as:

Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
Urinary urgency - This can be described as a sudden and compelling need to urinate.
Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
Hematuria - Hematuria is visible blood in the urine.
Incontinence - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using 3-MeO-PCMo on a daily or even weekly basis and manually limiting one’s usage of the substance.

Legal issues:

3-MeO-PCMo is currently a legal grey area drug worldwide and is freely available through the use of online research chemical vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.

Within the U.K. specifically, as 3-MeO-PCMo is the morpholine analogue of 3-MeO-PCP, it is therefore an arylcyclohexylamine (ACH) that is not controlled in the U.K. because a morpholine substituion on the amine is not proscribed by the country’s generic ACH laws.

Conclusion:

3-MeO-PCMo is by far the closest experience to that of MXE or ketamine currently available in the U.K. legal research chemical market. Its absurd lack of potency, however, makes it unusable for regular usage due to its proportionally adverse effects on the bladder.

This substance breakdown was written through collaboration between PsychonautWiki contributors Kaylee, Josikins and Oscarette. The full article is available here.

Jul 20, 201513 notes

Ephenidine, broken down and described

Dosage (oral)
Threshold: 50 - 75mg
Light: 75 - 110mg
Common: 110 - 150mg
Strong: 150 - 200mg
Heavy: > 200mg +

Duration (oral)
Total duration: 5 - 7 hours
Onset: 10 - 30 minutes

Ephenidine (N-Ethyl-1,2diphenylethylamine) is a dissociative NMDA receptor antagonist and anesthetic drug of the phenethylamine chemical class. It has similar effects to that of the arylcyclohexylamine and morphinan classes of dissociatives.

This compound induces a state referred to as “dissociative anesthesia” and is used as a recreational drug. Very little is known about this substance, but it has recently become freely available through online research chemical vendors where it is being sold as a designer drug. Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other piperidine dissociatives such as diphenidine and methoxphenidine.

In terms of its chemistry, ephenidine is a molecule of the diarylethylamine class. It contains a substituted phenethylamine skeleton with an additional phenyl ring bound to R_α. An ethyl chain is bound to the terminal amine R_N of the phenethylamine. Ephenidine is structurally analogous to diphenidine and MXP, but is not a piperidine dissociative. Ephenidine shares a diphenylethylamine skeleton with diphenidine and MXP, but lacks a piperidine substitution.

In terms of its pharmacology, no formal studies have been carried out. However, ephenidine is thought to act as an NMDA receptor antagonist due to its structural similarities to diphenidine. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. NMDA receptor antagonists close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually the famous “hole.” This compound induces considerable stimulation at higher doses which suggests that it might function as a serotonin, dopamine and noradrenaline reuptake inhibitor in a similar manner to other dissociatives.

Physical effects:

The subjective physical effects of ephenidine can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:

Tactile disconnection
Spontaneous tactile sensations - The ephenidine body high is a soft and pleasurable tingling sensation which is motionless and all-encompassing with no specific location.
Stimulation - This compound provides stimulating effects at lower dosages which are less intense than that of diphenidine or methoxphenidine.
Tactile suppression - This partially to entirely suppresses one’s sense of touch, creating feelings of numbness within the extremities. It is responsible for the anaesthetic properties of this substance.
Motor control loss - A loss of gross and fine motor control alongside of balance and coordination is prevalent within the ephenidine experience and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless one is experienced) in case of falling over and injuring oneself.
Decreased bodily weight - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
Physical autonomy
Increased heart rate

Cognitive effects:

The general head space of ephenidine is often described as particularly euphoric and clear-headed in comparison to that of DXM and ketamine. The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:

Visual effects:

Suppressions:

This substance does not enhance visual stimuli; instead, it tends to degrade and decrease visual aptitude in a variety of ways which generally include:

Visual disconnection - This eventually results in the ephenidine equivalent of the famous “k-hole” or, more specifically, holes, spaces and voids alongside of structures. However, it is worth noting that particularly heavy dosages must be consumed to reach the deepest state of this component in comparison to other more classical dissociatives such as ketamine or methoxetamine.
Visual acuity suppression
Double vision - This component is prevalent at moderate to heavy dosages and makes reading impossible unless one closes an eye.
Pattern recognition suppression - This effect generally occurs at higher dosages and makes one unable to recognize and interpret perceivable visual data.

Distortions:

Ephenidine exhibits a full array of dissociative distortions and alterations in visual perception which generally includes:

Drifting (melting, flowing, breathing and morphing) - In comparison to other dissociatives, this effect is more prominent than ketamine, MXE, diphenidine and methoxphenidine. The visual drifting is simplistic, slow and smooth in motion, static in appearance and unrealistic/cartoon-like in style.
Perspective distortions
Scenery slicing

Geometry:

The visual geometry found within ephenidine can be described as very distinct and psychedelic when compared to that of ketamine, MXE, methoxphenidine and diphenidine. It is considerably less detailed than that of DXM. It does not extend beyond level 5 and can be comprehensively described through its variations as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.

Hallucinatory states:

At high doses, ephenidine can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics. These effects include:

Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - In comparison to other dissociatives, this effect can occur at heavy dosages, but is considerably less common than the same effect found within psychedelics and deliriants. It can be comprehensively described through its variations as delirious in believability, fixed in style, equal in new experiences and memory replays in content, autonomous in controllability and solid in style.

Auditory effects:

The auditory effects are common in their occurrence and exhibit a range of effects which commonly includes:

Physical health effects, potential addiction and tolerance:

The toxicity and long-term health effects of recreational ephenidine use have not been studied in any scientific context and the exact toxic dosage is unknown. This is because ephenidine is a research chemical with very little history of human usage. Anecdotal evidence from people who have tried ephenidine within the psychonaut community suggests that there are no negative health effects attributed to simply trying this drug at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed).

There is a very strong tolerance build up with ephenidine which results in the need to consume increasingly large doses in order to achieve the same level of effects. This should reset to baseline after 1 - 2 weeks. There may be some addictive potential, but this is still unknown.

Legal issues:

Ephenidine is currently a legal grey area drug worldwide and is freely available through the use of online research chemical vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.

Conclusion:

In conclusion, ephenedine is a deeply profound dissociative which presents a full range of effects at high enough doses. Although it is not an MXE replacement, it is perhaps the best novel dissociative to recently arrive on the legal research chemical scene and is superior to that of diphenidine or MXP in my opinion.

This substance breakdown was written through collaboration between PsychonautWiki contributors Kaylee, PJosepherum, Josikins and Oscarette. The full article is available here.

Jul 1, 201522 notes